Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Cardiovascular Drugs Market Outlook

The global cardiovascular drugs market size attained a value of USD 66.70 billion in 2023. The market is anticipated to grow at a CAGR of 2.7% during the forecast period of 2024-2032, driven by the rising prevalence of cardiovascular diseases across the globe. The global cardiovascular drugs market share is anticipated to achieve a value of USD 84.47 billion by 2032.

Global Cardiovascular Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America to Lead the Global Cardiovascular Drugs Market

North America dominates the global cardiovascular drugs industry, owing to the increased awareness about various heart diseases within the region. The United States represent the most important marketplace for cardiovascular drugs followed by Canada in North America. On the other hand, Asia Pacific is predicted to witness high growth rates in the coming years, thanks to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labour attracts manufacturing companies which is further boosting the growth in the Asia Pacific region.

Additionally, increasing awareness about heart related problems is supporting within the growth of cardiovascular drugs market within the region. China, India, and Japan are expected to be the fastest growing cardiovascular drugs markets thanks to rising cases of heart diseases and extensive pipeline drugs. Increasing ageing population and rising number of lifestyle diseases are also contributing to the growth of global cardiovascular drugs industry.

Cardio Vascular Drugs: Market Segmentation

Cardiovascular drugs refer to agents used for the treatment of diseases related to the cardiovascular system, which include blood clots, stroke, arteria coronaria disease, variation in vital sign, arrhythmias, high cholesterol, and coronary failure.

Global Cardiovascular Drugs Market By Drug Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cardiovascular drugs can be divided on the basis of drug type into:

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiarrhythmics
  • Others

On the basis of disease indication, cardiovascular drugs can be divided into:

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

Cardiovascular drugs can be segmented on the basis of distribution channel into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

The regional markets for global cardiovascular drugs industry can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Global Cardiovascular Drugs Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Cases of Cardiovascular Diseases Boosting the Global Cardiovascular Drugs Industry

Cardiovascular drugs are extremely helpful in treating various heart related dysfunction. The rising prevalence of heart stroke and cardiovascular diseases is one among the key reasons for the expansion of the cardiovascular drugs market. Cardiovascular diseases have shown stable increase in prevalence worldwide, driven by numerous modern lifestyle changes. Factors like sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors liable for the rise within the number of cardiovascular disorders among the young population. A number of the opposite crucial drivers for global cardiovascular drugs industry growth is that the increased awareness regarding cardiovascular health and therefore the corresponding increase in product launches. The rising number of diabetic patients holds immense potential to the expansion of worldwide cardiovascular drugs industry.

Key Industry Players in the Global Cardiovascular Drugs Market

The report gives a detailed analysis of the following key players in the global cardiovascular drugs industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Group
  • Pfizer Inc.
  • Lupin
  • GSK Plc
  • Glenmark Pharmaceuticals Inc.
  • Capricor Therapeutics
  • Zensun

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Indications
  • Route of Administration
  • Drug Type
  • End User
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Antihypertensive Drugs
  • Anticoagulants
  • Antiplatelet Agents
  • Antihyperlipidemic Drugs
  • Antiarrhythmic Drugs
  • Others
Breakup by Indications
  • Hypertension
  • Coronary artery disease
  • Heart Failure
  • Arrhythmias
  • Dyslipidemia
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by Drug Type
  • Branded
  • Generics
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Breakup by Distribution Channel
  • Hospitals Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Group
  • Pfizer Inc.
  • Lupin
  • GSK Plc
  • Glenmark Pharmaceuticals Inc.
  • Capricor Therapeutics
  • Zensun

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The global cardiovascular drugs market is projected to grow at a CAGR of 2.7% between 2024 and 2032.

The major drivers of the market include the sedentary lifestyle, excess consumption of alcohol, stress and smoking, increased awareness regarding cardiovascular health, unhealthy eating habits, increasing ageing population, and rising number of lifestyle diseases.

The rising prevalence of heart stroke and cardiovascular diseases and the rising number of diabetic patients are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Cardiovascular drugs can be divided on the basis of drug type into antihypertensive, antihyperlipidemic, anticoagulants, and antiarrhythmics, among others.

Based on disease indication, cardiovascular drugs can be divided into hypertension, hyperlipidemia, coronary artery disease, and arrhythmia, among others.

The distribution channels include hospital pharmacies, retail pharmacies, and online, among others.

The major players in the industry are Baxter International Inc., Pfizer Inc., Bayer AG, Johnson & Johnson Services, Inc., Novartis AG, and Boehringer Ingelheim International GmbH, among others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124